VK 2735
Alternative Names: VK-2735Latest Information Update: 28 Aug 2025
At a glance
- Originator Viking Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity
- Phase I Non-alcoholic steatohepatitis
- Preclinical Diabetes mellitus
Most Recent Events
- 19 Aug 2025 Updated efficacy and adverse event data from the phase II VENTURE trial in Obesity released by Viking therapeutics
- 23 Jun 2025 Phase-III clinical trials in Obesity in Puerto Rico (SC) (NCT07104500)
- 23 Jun 2025 Viking Therapeutics initiates the phase III VANQUISH-2 trial for Obesity in Puerto Rico (SC, Injection) (NCT07104383)